Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$3.8MCash on Hand
3.6mo Cash Runway
Follow AZTR by emailGet an email when AZTR reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about AZTR, unsubscribe in one click. Privacy
📣 What AZTR Says Is Next
Q4 · “Topline data from first cohort of Phase 1/2 trial expected in Q4 - 2026.”
Company press release, Nov 12, 2026 · SEC filing
by year-end 2026 · “First-in-human cosmetic study planned with initial results expected by year-end 2026.”
Company press release, Nov 12, 2026 · SEC filing
fourth quarter of 2026 · ATR-04: “We are encouraged by the potential to reach additional patient populations and look forward to reporting topline data from Cohort 1, which we anticipate in the fourth quarter of 2026.” Salva concluded: “The remainder of 2026 has the potential to be a defining period for Azitra as we expect to report initial results from our first in-human cosmetic study of ATR-COSF and topline data from Cohort 1 of our ATR-04 Phase 1/2 trial.”
Company press release, Nov 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 12, 2026 ·
Earnings Reported Q3 2026 net loss of $3.0 million, up from $2.8 million a year earlier, with R&D of $1.3 million and G&A of $1.6 million. Cash and equivalents were $3.8 million at September 30, 2026. Completed Cohort 1 of the ATR-04 Phase 1/2 trial and expects topline data in Q4 2026. Form 8-K · SEC filing · Press release
Nov 10, 2026 ·
Clinical trial Azitra will present ATR-COSF data at BIO-Europe in Cologne on November 10, 2026, showing a 56% reduction in wrinkles from baseline in an ex vivo human torso model and improved elasticity in a second model at 4% formulation. Initial first-in-human ATR-COSF results are expected by year-end. Form 8-K · SEC filing · Press release
Oct 29, 2026 ·
Clinical trial Expanded eligibility for the ATR-04 Phase 1/2 trial to include patients with rash from KRAS and MEK inhibitors, plus NF1 patients with MEK inhibitor-associated rash. The amendments also shorten washout periods for antibiotics and steroids. Form 8-K · SEC filing · Press release
Oct 26, 2026 ·
Financing Azitra said it will not use its at-the-market offering program for the foreseeable future. From September 28 through October 26, 2026 it sold 1,000 shares for about $126 in gross proceeds. The company also issued a press release on ATR-COSF ex vivo skin data, with first-in-human initial results expected by year end. Form 8-K · SEC filing · Press release
Oct 22, 2026 ·
Listing Azitra will effect a 1-for-10 reverse stock split of its common stock, effective October 26, 2026 at 12:01 a.m. Eastern Time, with trading on NYSE American on a split-adjusted basis at market open that day. Fractional shares will be paid in cash. Form 8-K · SEC filing
Oct 1, 2026 ·
Clinical trial Azitra said the safety review committee cleared its Phase 1/2 ATR-04 trial to advance to Cohort 2 for EGFR inhibitor-associated skin rash, based on safety data from six patients. Cohort 2 is expected to enroll about 24 patients. Form 8-K · SEC filing · Press release
Sep 28, 2026 ·
Financing Azitra filed a prospectus supplement for an at-the-market offering of up to $3,503,232 of common stock through sales agent A.G.P., which will receive a 3.0% cash fee on gross proceeds. The stock closed at $0.1680 on September 25, 2026. Form 424B5 · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Jul 2027 · Phase 1/2 · Recruiting · A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
AZTR holds $3.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $3.1M/quarter from operations,
an estimated runway of 3.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:80 · High
Cash runway 4 months +40
ATM program on file since Sep 2026 +15
Shelf registration (S-3, Jul 2024) +10
Going-concern doubt in the latest 10-Q +15As of the date of this filing, management has determined there is substantial doubt about our ability to continue as a going concern based on our lack of revenue from commercial operations, significant losses, and the need to raise additional capital to support ongoing operations.10-Q, Nov 2026
Share count 6,060,435 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full AZTR picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AZTR and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.